Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepati | An observational study from Washington University in St.
Alzheimer's disease is likely caused by stalled protein processing in the brain, according to a new study.
Verywell Health on MSN21h
Injectable Alzheimer's Drugs Could Save Patients Trips to the HospitalEisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Alzheimer’s is the most common form of dementia — it causes memory loss, confusion, thinking problems and behavioral changes.
"This research highlights the potential for aerobic exercise to serve as a cornerstone in preventive strategies for Alzheimer ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
There’s no polite way to discuss this, but so blow the winds of change. The term “fart walks” is trending right now, though ...
New drug approvals and a federal dementia care pilot program among the year's significant developments, according to the ...
The geroscience hypothesis focuses on extending the healthy lifespan by targeting aging mechanisms. Recent advances in ...
Seasonal affective disorder (SAD) is a type of recurrent depressive periods that occur during the same season each year. SAD ...
The gene mutation was isolated in a family in northern Italy where under half of the relations developed the disease. View on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback